Precigen, Inc. (NASDAQ: PGEN)

Precigen, Inc., a biopharmaceutical company (NASDAQ: PGEN), operates in the healthcare sector, specifically in the development of gene and cell therapies. The company's mission is to improve outcomes for patients with significant unmet medical needs by leveraging its proprietary technology platforms. These platforms are designed to enable precise control of gene expression and modification of biological molecules to treat underlying disease conditions.

Precigen's technology platforms include UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics. The UltraCAR-T platform is a proprietary technology that allows for the construction of powerful gene programs to drive efficacy, deliver multigenic constructs using viral and non-viral approaches, and control gene expression in vivo. This platform is optimized to address the shortcomings of current CAR-T approaches, such as complex and lengthy manufacturing processes and the need for ex vivo expansion.

The company's AdenoVerse immunotherapy platform provides a unique approach to activating the immune system to recognize and target HPV+ solid tumors. Precigen's most advanced programs based on this platform include PRGN-2012, a first-in-class, investigational "off-the-shelf" AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with HPV type 6 or HPV type 11. PRGN-2009, another advanced program, is a first-in-class, investigational "off-the-shelf" immunotherapy designed to activate the immune system to recognize and target HPV+ solid tumors.

Precigen's competitive advantages include its proprietary technology platforms, which provide a strong foundation for advancing precision medicine. The company's UltraCAR-T platform enables the construction of powerful gene programs to drive efficacy, deliver multigenic constructs using viral and non-viral approaches, and control gene expression in vivo. The company's AdenoVerse immunotherapy platform provides a unique approach to activating the immune system to recognize and target HPV+ solid tumors.

Precigen's position within the industry is unique, with a focus on developing innovative gene and cell therapies to address significant unmet medical needs. The company's competitive advantages, including its proprietary technology platforms and expertise in immunology, position it well for success in the development of new therapies.

Precigen's primary customers are patients with significant unmet medical needs, including those with RRP and HPV-associated cancers. The company's therapies are designed to provide improved outcomes for these patients, and the company is working to make these therapies available to patients through partnerships with healthcare providers and payers.

The brand names and/or trade names of its products and services include UltraCAR-T, AdenoVerse immunotherapy, ActoBiotics, PRGN-2012, PRGN-2009, and PRGN-3005. Each of these products and services represents a significant advancement in the field of gene and cell therapies, and Precigen is committed to continuing its research and development efforts to bring new and innovative treatments to market.